Health Canada Approves VRAYLAR® for the Treatment of Bipolar l Disorder and Schizophrenia in Adults

VRAYLAR ® is a new atypical antipsychotic medication with partial agonist activity at central dopamine D 3 receptors in addition to targeted activity at D 2 and serotonin 5-HT 1A and 5-HT 2A receptors. 1

ABBVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company announced today that Health Canada has approved VRAYLAR ® (cariprazine) as monotherapy for the acute management of manic, mixed, and depressive episodes associated with bipolar l disorder in adults, as well as the treatment of schizophrenia in adults. 1

AbbVie Canada. (CNW Group/AbbVie Canada)

Bipolar I disorder is a mental illness characterized by extreme mood swings that can impact an individuals' ability to think, behave and function. 2 It can consist of three states which includes manic, depressive, and mixed episodes. 3 While the causes of bipolar I disorder are unknown, biological factors can play a role and can be difficult to diagnose due to the wide range of symptoms. 3

Schizophrenia is a severe mental illness that can also impact a person's ability to function, and often presents symptoms that can change over time. Symptoms can include hallucinations, disorganized speech, social withdrawal, and catatonic behaviour. 3

"I have seen firsthand what impact bipolar l disorder and schizophrenia can have on a person's life. These are complex illnesses that can be difficult to treat and manage. It is important that we have additional treatment options available for persons affected," says Dr. Roger S. McIntyre , M.D., FRCPC, Professor of Psychiatry and Pharmacology, University of Toronto . "As a healthcare professional, I am pleased to hear that this treatment is now available for Canadians who live with bipolar l disorder or schizophrenia."

It's estimated 2.2% of Canadians will experience bipolar l disorder in their lifetime and can impact both men and women equally, 4 while an estimated 300,000 Canadians are impacted by schizophrenia. 3 Stigma remains prevalent in both disorders, with patients often experiencing discrimination and difficulty in accessing resources and treatment. 5

"We know that living with bipolar l disorder can present various challenges impacting the daily lives of patients and their families," Dave Gallson , National Executive Director, Mood Disorders Society of Canada . "The Mood Disorders Society of Canada thanks Health Canada for the approval of VRAYLAR ® , which will support those in the community in managing this mental illness. It is encouraging to see new treatment options for people with bipolar I disorder."

"We are pleased to see the progress in new treatments to support Canadians living with schizophrenia," says Chris Summerville , CEO of the Schizophrenia Society of Canada . "Patients are looking for convenient and safe treatments to support their health and recovery. VRAYLAR ® will offer new hope for many Canadians and help minimize the burdens associated with schizophrenia to support patients and their caregivers."

"Mental illness affects many Canadians either through personal experience, or that of a family member, friend, or colleague," says Tracey Ramsay, Vice President and General Manager, AbbVie Canada. "The approval of VRAYLAR ® is an important milestone that will support patients suffering from bipolar I disorder and schizophrenia. At AbbVie, we are committed to providing new treatment options to enhance patient care and support the unmet needs of mental illness community."

About   VRAYLAR ® (cariprazine) 1
VRAYLAR ® is an oral, once daily atypical antipsychotic approved as monotherapy for the acute management of manic, mixed, and depressive episodes associated with bipolar l disorder in adults, as well as the treatment of schizophrenia in adults.

The mechanism of action of cariprazine in schizophrenia and bipolar I disorder is unknown. However, the therapeutic effect of cariprazine may be mediated through a combination of partial agonist activity at central dopamine D 3 , D 2 and serotonin 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors. Cariprazine forms two major metabolites, desmethyl cariprazine (DCAR) and didesmethyl cariprazine (DDCAR), that have in vitro receptor binding and functional activity profiles similar to the parent drug.

VRAYLAR ® is contraindicated in patients who are hypersensitive to cariprazine or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.  VRAYLAR ® is also contraindicated with concomitant use with strong and moderate CYP3A4 inhibitors / inducers. Due to the slow elimination of cariprazine and its metabolites, treatment with strong and moderate CYP3A4 inhibitors must be initiated at least 2 weeks after VRAYLAR discontinuation.

VRAYLAR is being developed jointly by AbbVie and Gedeon Richter Plc, with AbbVie responsible for commercialization in the U.S., Canada , Japan , Taiwan and certain Latin American countries (including Argentina , Bolivia , Brazil , Chile , Colombia , Ecuador , Mexico , Peru and Venezuela ).

Please consult the VRAYLAR ® Product Monograph at www.allergan.ca .

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.ca . Follow AbbVie Canada on Twitter , on Instagram or find us on LinkedIn.

1 VRAYLAR Product Monograph. Allergan Inc. April 22nd 2022.

2 CAMH. Bipolar Disorder. Retrieved from https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/bipolar-disorder . Accessed March 2022.

3 Schizophrenia Society of Canada. Learn more about Schizophrenia. Retrieved from https://schizophrenia.ca/learn-more-about-schizophrenia/ . Accessed March 2022.

4 Canadian Psychological Association. "Psychology Works" Fact Sheet: Bipolar Disorder. Retrieved from https://cpa.ca/psychology-works-fact-sheet-bipolar-disorder/ . Accessed March 2022.

5 CAMH. Addressing Stigma. Retrieved from https://www.camh.ca/en/driving-change/addressing-stigma . Accessed March 2022.

SOURCE AbbVie Canada

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/April2022/27/c4557.html

News Provided by Canada Newswire via QuoteMedia

ABBV
The Conversation (0)
Health Canada Approves AbbVie's RINVOQ®  for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

- Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at week 14 versus placebo 1
- RINVOQ is the first and only Janus Kinase (JAK) inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in Canada 1, 2, 3

AbbVie (NYSE: ABBV), today announced that Health Canada has approved RINVOQ ® (upadacitinib, 15 mg), the first oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have had an inadequate response to a biologic disease modifying anti-rheumatic drug (DMARD) or when use of those therapies is inadvisable.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

- Oral presentations highlight efficacy and safety outcomes from the upadacitinib (RINVOQ ® ) clinical trial program in adults with moderately to severely active Crohn's disease, and investigational use of linaclotide (LINZESS ® ) in treating functional constipation in pediatric patients aged 6 to 17 years

- Twenty-nine abstracts showcase AbbVie's   vast portfolio and continued commitment to changing the way patients living with gastrointestinal disorders manage their condition

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona's patents for TFC-1067 and related family of compounds.

"We are very pleased to have finalized terms with a global leader in medical aesthetics and the innovator behind SkinMedica™, a leader in the science of skin rejuvenation," said Dr. Howard Verrico, CEO of Sirona Biochem. "Our most recent clinical trial of TFC-1067 was a collaborative effort with Allergan Aesthetics to demonstrate the clinical potential in topical skin care treatments. This further validates our platform technology as viable for additional commercial products which we are actively pursuing. We would like to thank Dr. Linda Pullan of Pullan Consulting who assisted with our current success."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Cizzle Brands Secures Distribution for CWENCH Hydration at MacEwen-Owned Gas Stations in Ontario and Quebec

Cizzle Brands Secures Distribution for CWENCH Hydration at MacEwen-Owned Gas Stations in Ontario and Quebec

The availability of CWENCH Hydration at 54 MacEwen-owned Esso , Shell , MacEwen and Quickie gas stations is a direct result of the recently announced distribution agreement between Cizzle Brands Corporation and Keurig Dr Pepper Canada subsidiary Van Houtte Coffee Services ("VHCS"), which distributes to over 30,000 commercial sites across Canada. This agreement with VHCS has already yielded meaningful results in helping to commercialize CWENCH Hydration™.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE

Amgen (NASDAQ: AMGN) will present at the 35 th Annual Oppenheimer Healthcare Life Sciences Conference at 11:20 a.m. ET on Wednesday Feb. 12, 2025. Narimon Honarpour, senior vice president of global development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE

Amgen (NASDAQ: AMGN) will present at the 35 th Annual Oppenheimer Healthcare Life Sciences Conference at 11:20 a.m. ET on Wednesday Feb. 12, 2025. Narimon Honarpour, senior vice president of global development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cizzle Brands Corporation Becomes Title Sponsor of the CWENCH All Canadian Volleyball Games

Cizzle Brands Corporation Becomes Title Sponsor of the CWENCH All Canadian Volleyball Games

Entering its third year, the CWENCH All Canadian Volleyball Games is Canada's premier girls' volleyball event. Set to take the national stage with live streaming on CBC Gem, the event features 60 of Canada's top-performing girls' volleyball players in each of the 17U and 16U age categories. As a proudly Canadian house of brands, this sponsorship is part of Cizzle Brands' ongoing initiatives to support youth sports in Canada.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

"Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong performance globally, we are investing heavily in our rapidly advancing pipeline to deliver innovative therapies across our four therapeutic areas," said Robert A. Bradway , chairman and chief executive officer.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×